Top Page
Paragon Care Limited
(Sydney:PGC)
Paragon Care Limited (PGC) vs. iShares MSCI Australia ETF (EWA)
Paragon Care Limited Business Overview & Revenue Model
Paragon Care Limited Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.61B | 3.61B | 2.97B | 307.63M | 237.62M | 235.84M |
| Gross Profit | 324.00M | 324.00M | 176.07M | 51.68M | 36.58M | 33.41M |
| EBITDA | 89.81M | 89.81M | 43.18M | 37.07M | 23.96M | 26.54M |
| Net Income | 20.57M | 20.57M | 8.38M | 12.80M | 6.63M | 8.28M |
Balance Sheet | ||||||
| Total Assets | 1.23B | 1.23B | 1.13B | 448.52M | 438.44M | 291.92M |
| Cash, Cash Equivalents and Short-Term Investments | 21.90M | 21.90M | 19.94M | 970.00K | 46.20M | 33.20M |
| Total Debt | 296.52M | 296.52M | 251.83M | 122.14M | 131.26M | 113.01M |
| Total Liabilities | 915.04M | 915.04M | 838.97M | 196.56M | 196.31M | 170.40M |
| Stockholders Equity | 319.00M | 319.00M | 291.92M | 18.88M | 235.82M | 121.52M |
Cash Flow | ||||||
| Free Cash Flow | -23.04M | -23.04M | 25.14M | -3.30M | 14.42M | 22.18M |
| Operating Cash Flow | -11.35M | -11.35M | 44.45M | 17.75M | 19.03M | 27.46M |
| Investing Cash Flow | -16.64M | -16.64M | -19.52M | -31.75M | 7.07M | -18.80M |
| Financing Cash Flow | 28.65M | 28.65M | -5.95M | -10.00M | -11.93M | 32.00K |
Paragon Care Limited Technical Analysis
Paragon Care Limited Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | AU$524.76M | 15.92 | 18.59% | 4.60% | 6.73% | 37.16% | |
53 Neutral | AU$35.48B | 61.07 | ― | 0.44% | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | AU$653.52M | -1.24 | -67.21% | ― | -23.02% | 33.11% | |
48 Neutral | AU$347.61M | 16.94 | 6.74% | ― | 21.68% | 37.78% | |
47 Neutral | AU$216.71M | -2.35 | -90.93% | ― | 456.50% | -457.14% | |
38 Underperform | AU$227.49M | -2.42 | -21.13% | ― | 5.07% | 46.14% |
Paragon Care Limited Corporate Events
Paragon Care will cease acting as the primary wholesaler to Ramsay Healthcare’s retail and hospital pharmacy operations from 1 February 2026 after its re-tender bid was undercut by a lower-priced competitor, a contract that added about A$230 million to FY25 revenue but less than 2% to gross margin. Management expects the exit to have an immaterial impact on FY26 earnings as it strips out associated supply chain costs, while the release of roughly A$4.5 million in working capital will be used to pay down debt, reinforcing a strategic focus on higher-margin business, strong underlying healthcare demand and a reported A$1.9 billion in unaudited half-year group revenue.
The most recent analyst rating on (AU:PGC) stock is a Hold with a A$0.24 price target. To see the full list of analyst forecasts on Paragon Care Limited stock, see the AU:PGC Stock Forecast page.
Paragon Care Limited has disclosed a change in director David Collins’ indirect interest in the company, with Collins acquiring an additional 2,000,000 ordinary shares via an on‑market trade on 30 December 2025 at $0.2192 per share. The purchase, made through the Collins Millar Family account where Collins is a discretionary beneficiary, lifts his indirect holding to 477,507,317 ordinary shares, signalling a further alignment of the director’s financial interests with those of shareholders and underscoring confidence in the company’s prospects.
The most recent analyst rating on (AU:PGC) stock is a Hold with a A$0.20 price target. To see the full list of analyst forecasts on Paragon Care Limited stock, see the AU:PGC Stock Forecast page.
Paragon Care Limited has corrected three previously lodged Appendix 3Y Change of Director’s Interest Notices after identifying an administrative error in how certain director share transactions were described. The company stated that trades reported on 23 and 24 December 2025 were incorrectly recorded as on‑market transactions and have now been reclassified as off‑market trades, with no other alterations to the original disclosures, signalling that the underlying holdings data remains unchanged for investors and regulators.
The most recent analyst rating on (AU:PGC) stock is a Hold with a A$0.20 price target. To see the full list of analyst forecasts on Paragon Care Limited stock, see the AU:PGC Stock Forecast page.
Paragon Care Limited has disclosed a change in the shareholding of director John Walstab, who holds both direct and indirect interests in the company’s fully paid ordinary shares. The filing shows that Walstab acquired 1,000,000 Paragon Care shares via an on-market trade at $0.18 per share on 19 December 2025, increasing his total holding to 145,591,185 shares, a move that modestly strengthens insider ownership and may be interpreted by investors as a signal of confidence in the company’s outlook.
The most recent analyst rating on (AU:PGC) stock is a Hold with a A$0.20 price target. To see the full list of analyst forecasts on Paragon Care Limited stock, see the AU:PGC Stock Forecast page.
Paragon Care Limited has disclosed a change in the indirect interests of director David Collins, whose holdings are associated with the Collins Millar Family account. Collins increased his indirect stake in the company by acquiring 3 million ordinary shares in an on-market trade at $0.1804 per share on 19 December 2025, lifting his total indirect holding from 472.5 million to 475.5 million shares. The company confirmed there were no related changes in contracts and that the transaction did not occur during a closed trading period, signalling routine portfolio adjustment rather than a compliance event.
The most recent analyst rating on (AU:PGC) stock is a Hold with a A$0.20 price target. To see the full list of analyst forecasts on Paragon Care Limited stock, see the AU:PGC Stock Forecast page.
Paragon Care Limited has disclosed a change in director Carmen Riley’s shareholding, as required under ASX listing rules. The transaction shows Riley acquired 2,000,000 ordinary shares in an on‑market trade at $0.18 per share on 22 December 2025, increasing her holding to 2,538,888 ordinary shares while retaining 7,480,252 performance rights; no related contracts or trades during a closed period were involved, indicating a straightforward increase in her equity stake that may be interpreted by investors as a sign of confidence in the company.
The most recent analyst rating on (AU:PGC) stock is a Hold with a A$0.20 price target. To see the full list of analyst forecasts on Paragon Care Limited stock, see the AU:PGC Stock Forecast page.
Paragon Care Limited has reacted to the appointment of administrators for 54 pharmacies within the Infinity Retail Pharmacy Group, expressing surprise and disappointment over the decision, which came unexpectedly amidst ongoing efforts to implement a payment and debt restructuring plan. The company aims to collaborate with receivers, administrators, and stakeholders to facilitate an orderly sale or recapitalization process, aiming to maximize creditor returns and mitigate impacts for stakeholders within the healthcare industry.
The most recent analyst rating on (AU:PGC) stock is a Hold with a A$0.23 price target. To see the full list of analyst forecasts on Paragon Care Limited stock, see the AU:PGC Stock Forecast page.
Paragon Care Limited has completed the acquisition of the Somnotec Group, excluding its Thailand business, which awaits a foreign business license. The acquisition strengthens Paragon Care’s presence in the Asia Pacific healthcare market, although the pending Thailand acquisition, contributing 17.5% of Somnotec’s EBITDA, is expected to finalize in 6 to 12 months.
The most recent analyst rating on (AU:PGC) stock is a Hold with a A$0.23 price target. To see the full list of analyst forecasts on Paragon Care Limited stock, see the AU:PGC Stock Forecast page.
Paragon Care Limited announced a change in the director’s interest, with Director Carmen Riley acquiring additional ordinary shares. This transaction, conducted through an on-market trade, increases Riley’s holdings and reflects confidence in the company’s future prospects, potentially impacting stakeholder perceptions positively.
The most recent analyst rating on (AU:PGC) stock is a Hold with a A$0.26 price target. To see the full list of analyst forecasts on Paragon Care Limited stock, see the AU:PGC Stock Forecast page.
Paragon Care Limited announced a change in the director’s interest, with Carmen Riley acquiring 3,018,108 Performance Rights, as approved at the company’s Annual General Meeting. This change reflects the company’s ongoing commitment to aligning its leadership’s interests with its strategic goals, potentially impacting its operational focus and stakeholder engagement.
The most recent analyst rating on (AU:PGC) stock is a Hold with a A$0.26 price target. To see the full list of analyst forecasts on Paragon Care Limited stock, see the AU:PGC Stock Forecast page.
Paragon Care Limited has announced its acquisition of Haju Medical, a leading provider of medical aesthetic services and technology in Indonesia. This strategic acquisition is expected to enhance Paragon Care’s presence in the Asia Pacific region and complement its existing business operations in Thailand and other emerging markets. The acquisition, valued at A$70 million, is anticipated to be earnings accretive for Paragon Care in FY26 and will be funded through existing working capital facilities. The completion of the acquisition is expected by January 2026, subject to customary conditions.
The most recent analyst rating on (AU:PGC) stock is a Buy with a A$0.50 price target. To see the full list of analyst forecasts on Paragon Care Limited stock, see the AU:PGC Stock Forecast page.
Paragon Care Limited held its 2025 Annual General Meeting, where all resolutions, including the adoption of the remuneration report, election and re-election of directors, adoption of an omnibus equity plan, and issuance of performance rights to the CEO, were carried with overwhelming support. This indicates strong shareholder confidence in the company’s leadership and strategic direction, potentially strengthening its position in the healthcare industry.
The most recent analyst rating on (AU:PGC) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Paragon Care Limited stock, see the AU:PGC Stock Forecast page.
Paragon Care Limited’s 2025 Annual General Meeting highlighted the successful integration of CH2, Oborne Health Supplies, and ParagonCare, with ongoing improvements in IT and finance systems. The company launched new business units in aesthetics, robotics, and dental, and completed the acquisition of Somnotec Group to expand its Asian operations. Despite higher debt levels due to non-payment by Infinity Retail Pharmacy Group and high stock levels, the company is working on debt reduction plans. The transition of CEO duties from David Collins to Carmen Riley is progressing smoothly, and the company is focused on future growth opportunities, with potential dividend considerations for shareholders.
The most recent analyst rating on (AU:PGC) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Paragon Care Limited stock, see the AU:PGC Stock Forecast page.
Paragon Care Limited has announced the acquisition of Somnotec Group, a distributor of medical devices in Southeast Asia, to expand its footprint in the region. This strategic acquisition is expected to enhance Paragon Care’s service capabilities across the Asia Pacific, with the deal valued at SGD24 million. The acquisition is anticipated to be earnings accretive by FY26 and is subject to regulatory approvals and other conditions.
The most recent analyst rating on (AU:PGC) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Paragon Care Limited stock, see the AU:PGC Stock Forecast page.
Paragon Care Limited has announced a change in the director’s interest, with Director David Collins acquiring an additional 640,167 ordinary shares through an on-market trade. This acquisition increases his indirect holding to 472,507,317 shares, reflecting a strategic move that may influence the company’s market perception and stakeholder confidence.
The most recent analyst rating on (AU:PGC) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Paragon Care Limited stock, see the AU:PGC Stock Forecast page.
Paragon Care Limited announced a change in the director’s interest, with Director David Collins acquiring an additional 105,114 ordinary shares through an on-market trade. This acquisition increases his indirect holding to 471,867,150 shares, potentially indicating confidence in the company’s future performance and stability, which may positively influence stakeholder perceptions.
The most recent analyst rating on (AU:PGC) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Paragon Care Limited stock, see the AU:PGC Stock Forecast page.